The Matrix-Reconstruction Signal That No One Talks About

Most peptide skincare conversations stop at the big three. Argireline relaxes expression muscles. Matrixyl signals collagen production. GHK-Cu remodels damaged tissue. But there is a peptide that works deeper than all of them. Palmitoyl tripeptide-38 does not just stimulate one or two extracellular matrix proteins. It triggers a coordinated rebuild of six different structural components at once. Collagen types one, three, and four. Fibronectin. Hyaluronic acid. Laminin-five. If your skin’s extracellular matrix were a building under renovation, this peptide would be the general contractor showing up with the full crew instead of just the electrician.

Here is the number that matters. In a 2020 clinical study published in the Journal of Cosmetic Dermatology, a serum containing palmitoyl tripeptide-38 at just five parts per million reduced skin roughness by eight to nine percent in fifty-six days. Skin isotropy went up. Redness dropped by nine percent. Tone homogeneity improved by eight percent. And this was at a concentration so low it barely registers on a standard ingredient list. Let me break down how a three-amino-acid peptide with a fatty tail achieves this.

What Is Palmitoyl Tripeptide-38 — And Where Does It Come From?

Palmitoyl tripeptide-38 is a matrikine. That word matters. A matrikine is a peptide fragment that gets released when the body naturally breaks down extracellular matrix proteins. These fragments are not waste products. They are signals. When collagen or laminin degrades during normal tissue turnover, the resulting peptide fragments bind to fibroblast receptors and tell the cell “the matrix is being dismantled — rebuild it.” It is the body’s own maintenance feedback loop, repurposed as a cosmetic ingredient.

The peptide itself is a short chain of three amino acids: lysine, valine, and lysine, in that order. On its own, this tripeptide would never reach living fibroblasts. It is too water-soluble and too large to slip between corneocytes. That is where the “palmitoyl” part earns its place. A sixteen-carbon fatty acid chain is attached to the N-terminus of the tripeptide. This lipid tail makes the entire molecule lipophilic enough to partition into the stratum corneum’s lipid matrix and travel down to the dermis. The same strategy is used by Matrixyl, which attaches palmitic acid to the pentapeptide KTTKS.

Commercially, palmitoyl tripeptide-38 is sold under the trade name Matrixyl synthe’6 by Sederma, the French cosmetic ingredient company that also developed Matrixyl and Matrixyl 3000. The “synthe’6” in the name is literal marketing that reflects the science. This peptide stimulates the synthesis of six major extracellular matrix components. But Sederma does much of its development work in-house, and much of the mechanistic data lives in supplier white papers rather than peer-reviewed journals. The clinical studies that do exist in the published literature are combination-product trials where palmitoyl tripeptide-38 is one active among several. This is worth keeping in mind when evaluating claims.

How Palmitoyl Tripeptide-38 Works at the Molecular Level

Here is where the science gets genuinely interesting. Most signal peptides work through a single pathway. Palmitoyl pentapeptide-4 binds to a receptor that kicks off the TGF-beta cascade, which in turn prompts fibroblasts to make more collagen. It is a linear chain of events. One input, one output. Palmitoyl tripeptide-38 appears to work through a broader mechanism that touches multiple cellular programs simultaneously.

The peptide’s amino acid sequence — lysine-valine-lysine — mimics a fragment of the alpha-one chain of type one collagen. When this fragment docks with fibroblast surface receptors, it triggers a signaling cascade that upregulates not just collagen synthesis but the entire suite of proteins needed to build and anchor healthy extracellular matrix. Let me walk through each component that gets stimulated.

Collagen type one is the main structural protein in the dermis. It forms thick, rope-like fibrils that give skin its tensile strength. Without enough type one collagen, skin sags and thins. Collagen type three is the finer, more elastic collagen found in higher proportions in young skin. As we age, the ratio of type three to type one drops sharply. Restoring type three production helps skin feel softer and more resilient. Collagen type four is different from the first two. It does not form fibrils at all. Instead it creates the sheet-like basement membrane that separates the epidermis from the dermis. A healthy basement membrane is critical for nutrient exchange between skin layers and for preventing epidermal thinning. Fibronectin is the scaffold protein that organizes collagen fibrils into properly aligned bundles. Without it, new collagen would be a disorganized mess. Hyaluronic acid is the water-binding glycosaminoglycan that keeps the dermis hydrated and plump. Laminin-five anchors epidermal keratinocytes to the basement membrane through hemidesmosomes, which are the microscopic rivets that prevent the epidermis from separating from the dermis.

Six proteins. Six different structural roles. Stimulated by a single three-amino-acid signal. This breadth of action is what sets palmitoyl tripeptide-38 apart from simpler signal peptides. Palmitoyl pentapeptide-4 primarily boosts collagen types one and three, with some fibronectin activity. Palmitoyl tripeptide-38 adds basement membrane support, hyaluronic acid synthesis, and epidermal anchoring to the package. It is closer to a full matrix restoration signal than a collagen-only trigger.

Now here is the key data point. Sederma’s internal research, which is cited in their technical documentation for Matrixyl synthe’6, reports that after forty-eight hours of exposure to the peptide at three parts per million, human dermal fibroblasts showed a one hundred and twenty-four percent increase in hyaluronic acid synthesis relative to untreated controls. Collagen type one synthesis increased by roughly eighty percent. These are in vitro numbers from supplier data, so they come with the usual caveats. But the pattern is consistent with the mechanism. A broad-spectrum ECM signal produces broad-spectrum ECM results.

Getting Through the Wall — The Penetration Challenge

Every topical peptide faces the same gatekeeper. The stratum corneum. This outermost layer of skin is ten to twenty microns thick. It is a brick wall made of dead corneocytes embedded in a lipid mortar of ceramides, cholesterol, and free fatty acids. Anything larger than about five hundred daltons has a hard time getting through. Palmitoyl tripeptide-38 has a molecular weight of roughly six hundred and fifty daltons with the palmitoyl chain attached. That puts it in the “borderline possible” category for passive diffusion.

The palmitoyl group solves part of the problem. By making the peptide more lipophilic, it allows the molecule to dissolve into the lipid mortar between corneocytes and diffuse through the intercellular route. This is the same principle that allows topical retinoids and vitamin C derivatives to penetrate. It is not a perfect solution. The estimated flux through intact stratum corneum is low. At typical cosmetic concentrations of two to five parts per million in a leave-on serum, only a fraction of the applied peptide reaches viable epidermis and dermis.

But here is what most people miss. The concentration needed to trigger fibroblast activity is extremely low. Remember that three parts per million figure from the in vitro data. Topical formulations typically deliver between two and ten parts per million of the peptide to the skin surface. Even with a penetration efficiency of five to fifteen percent, the amount reaching the dermis appears to cross the threshold for biological activity. This is a peptide that works at catalytic doses. It does not need to accumulate. It just needs to reach the right receptors and deliver the signal.

Formulation matters enormously. Water-based serums with glycols like propanediol or butylene glycol enhance penetration by temporarily disrupting the lipid packing in the stratum corneum. Liposomal encapsulation, which wraps the peptide inside a phospholipid bilayer sphere, can increase dermal delivery by a factor of three to five. If you are choosing a product with palmitoyl tripeptide-38, look for formulations that include penetration enhancers or delivery vehicles. A peptide suspended in a basic carbomer gel will deliver far less than the same peptide in a liposomal serum.

What the Clinical Data Actually Shows

Let me walk through the three published clinical studies that include palmitoyl tripeptide-38. None of them test the peptide in isolation. That is important context. But together they paint a consistent picture of what this ingredient contributes to a well-designed formula.

The strongest evidence comes from the 2020 study by Lintner and colleagues in the Journal of Cosmetic Dermatology. Thirty women aged forty and older with visible photoaging applied a serum containing fifteen percent L-ascorbic acid, tocopheryl acetate, and palmitoyl tripeptide-38 at five parts per million once daily for fifty-six days. Skin roughness was measured using FOITS technology, which is fringe projection optical three-dimensional imaging. This is a quantitative, instrument-based method. It does not rely on subjective grading. The results showed statistically significant reductions in roughness parameters of eight to nine percent. Skin isotropy increased significantly. Redness decreased by nine percent. Tone homogeneity improved by eight percent. All results reached statistical significance with p-values below zero point zero five. The self-assessment questionnaires, completed every third day, showed that subjects perceived significant improvements in radiance, complexion evenness, and wrinkle appearance.

An earlier study by Sanz and colleagues published in the Journal of Cosmetic Dermatology in 2016 examined a serum combining apple stem cell extract, urea, creatine, and palmitoyl tripeptide-38. Thirty-two women with sensitive skin and crow’s feet wrinkles applied the serum twice daily for twenty-eight days. Seventy-one percent of subjects showed a clinically relevant anti-wrinkle effect. Visible improvement was noted in sixty-eight percent of subjects by day seven. Instrumental measurements confirmed a significant increase in dermal density and skin elasticity. The in vitro portion of the same study showed that the serum reduced mitochondrial reactive oxygen species production in senescent human fibroblasts and increased cellular ATP levels. This suggests the peptide does more than just trigger ECM synthesis. It may also support the metabolic health of aging fibroblasts.

A 2015 open-label clinical trial by Herndon and colleagues in the Journal of Drugs in Dermatology tested a multi-ingredient moisturizer containing palmitoyl tripeptide-38 alongside astragalus root extract, ursolic acid from rosemary, THD ascorbate, and coenzyme Q10. Thirty-seven women aged thirty-five to sixty applied the moisturizer twice daily for twelve weeks. Clinical grading at week eight showed statistically significant improvement across all parameters including fine lines, wrinkles, clarity, brightness, visual roughness, tactile roughness, and overall appearance. At week twelve the improvements were even more pronounced. The digital photography results supported the clinical grading. The product was rated as mild and well-tolerated with no statistically significant increase in any tolerability parameter.

So what do these three studies tell us? The peptide has never been tested alone in a published clinical trial. Every study is a combination product. This makes it impossible to attribute the results solely to palmitoyl tripeptide-38. But the mechanism data from in vitro work is specific and consistent. The clinical results across three different formulations all show improvements in roughness, tone, and wrinkle appearance. And the effects appear quickly. Within one to four weeks in the shorter-duration studies. That speed is more consistent with a signaling peptide that activates existing cellular machinery than with a slow collagen-building process that takes months to manifest visibly.

What Experienced Formulators Know That Ingredient Labels Hide

Here is the first anti-pattern. Many brands list palmitoyl tripeptide-38 on their ingredient label at a concentration that sounds impressive but is functionally useless. The peptide is typically supplied as a solution in water and glycerin at a concentration of roughly one hundred parts per million of the active peptide. A brand might add this solution at one percent of the formula, which sounds meaningful. But one percent of a solution containing one hundred parts per million peptide means the final product contains one part per million of palmitoyl tripeptide-38. That is below the three to five parts per million that the published studies used. Always check whether the listed concentration refers to the active peptide or the supplied solution. If the brand cannot tell you which, assume they are quoting the solution percentage.

The second thing experienced formulators know is that pH stability matters enormously for this peptide. Palmitoyl tripeptide-38 is most stable between pH four point five and pH six point five. Many popular exfoliating serums with alpha-hydroxy acids have a pH of three point five or lower. Layering a peptide serum on top of an AHA product without waiting twenty to thirty minutes can expose the peptide to a pH environment outside its stability range. The amide bonds in the peptide backbone start hydrolyzing. The palmitoyl group can detach. The peptide degrades before it ever reaches the dermis. This is not a reason to avoid either ingredient. It is a reason to separate them by time or to use them on alternating days.

The third pitfall is what the data does not tell you. None of the published studies measured long-term durability of results after product discontinuation. We do not know whether the improvements persist for weeks or months after stopping use. Based on what we know about ECM turnover kinetics in aging skin, the half-life of newly synthesized collagen in photoaged dermis is on the order of several months. But the hyaluronic acid and laminin effects likely dissipate faster. If you stop using the peptide, you should expect a gradual regression of the hydration and barrier improvements within a few weeks. The collagen and matrix organization benefits may persist longer. This is a maintenance ingredient, not a permanent fix.

Where Palmitoyl Tripeptide-38 Fits in a Peptide Routine

Now for the practical context. Palmitoyl tripeptide-38 is not a replacement for other signal peptides. It is a complement. Here is how I think about layering.

Matrixyl, which is palmitoyl pentapeptide-4, primarily stimulates collagen types one and three through the TGF-beta pathway. It is a targeted collagen signal. Palmitoyl tripeptide-38 stimulates collagen types one, three, and four plus fibronectin, hyaluronic acid, and laminin-five. It is a matrix-wide restoration signal. These two peptides target overlapping but distinct biology. Using them together makes logical sense. Each reinforces the other’s activity without competing for the same receptor or saturating the same pathway.

Argireline and other neurotransmitter-inhibiting peptides work on a completely different axis. They reduce expression muscle contraction. Combining a matrix-rebuilding peptide like palmitoyl tripeptide-38 with a muscle-relaxing peptide like Argireline targets both the structural and the dynamic causes of wrinkles. The peptide rebuilds the dermis from within while the neuropeptide prevents the repeated folding that creates expression lines at the surface.

GHK-Cu is a more complex partner. Both palmitoyl tripeptide-38 and GHK-Cu stimulate collagen synthesis. But GHK-Cu also promotes wound healing, angiogenesis, and antioxidant enzyme activity through its copper ion. Using them together could theoretically over-stimulate fibroblasts if both are at high concentrations. In practice, at the low concentrations used in cosmetics, this is unlikely to be a problem. But if you are using a high-concentration GHK-Cu serum at two percent or more alongside a separate palmitoyl tripeptide-38 product, alternate them on different days rather than layering both in the same routine.

One formulation partnership that works particularly well is palmitoyl tripeptide-38 with niacinamide. Niacinamide boosts NAD levels in fibroblasts, which supports the energetic demands of increased ECM protein synthesis. Niacinamide also strengthens the epidermal barrier through ceramide production. Palmitoyl tripeptide-38 strengthens the dermal-epidermal junction through laminin-five and collagen type four. Together they reinforce the entire skin structure from the surface lipid barrier down to the basement membrane. This is a synergy worth building a routine around.

Something to watch. The peptide skincare market is fragmenting into increasingly narrow signal peptides. Palmitoyl tripeptide-38 was ahead of this curve when Sederma launched Matrixyl synthe’6. But newer entrants like palmitoyl tripeptide-56 and palmitoyl tetrapeptide-72 are crowding the matrikine space. Whether these newer peptides offer genuine mechanistic advantages or are primarily exercises in supplier differentiation remains an open question. The clinical data for palmitoyl tripeptide-38, while not standalone, is stronger than what exists for most of the newer alternatives. I will be tracking this space as more head-to-head data emerges.

Further Reading

• Matrixyl Palmitoyl Pentapeptide-4: The Collagen Signaling Standard — How the original signal peptide works at the molecular level
• GHK-Cu Copper Peptide: The Science of Skin Regeneration — The wound-healing peptide with uniquely broad remodeling activity
• Peptide Stability in Skincare: pH, Formulation, and What Actually Survives — Why your expensive peptide serum might be degrading before it reaches your skin

Share this article:

Share on X · Share on LinkedIn · Share via Email

Last reviewed: July 2026. Peptide Proof Editorial Team.

Sources

• Lintner K, Gerstein F, Solish N. A serum containing vitamins C & E and a matrix-repair tripeptide reduces facial signs of aging. Journal of Cosmetic Dermatology. 2020 volume 19 issue 12 pages 3262 to 3269.
• Sanz MT, Campos C, Milani M, et al. Biorevitalizing effect of a novel facial serum containing apple stem cell extract, pro-collagen lipopeptide, creatine, and urea on skin aging signs. Journal of Cosmetic Dermatology. 2016 volume 15 issue 1 pages 24 to 30.
• Herndon JH Jr, Jiang L, Kononov T, Fox T. An Open Label Clinical Trial of a Multi-Ingredient Anti-Aging Moisturizer Designed to Improve the Appearance of Facial Skin. Journal of Drugs in Dermatology. 2015 volume 14 issue 7 pages 699 to 704.
• Jones RR, Castelletto V, Connon CJ, Hamley IW. Collagen stimulating effect of peptide amphiphile C16-KTTKS on human fibroblasts. Molecular Pharmaceutics. 2013 volume 10 issue 3 pages 1063 to 1069.
• Leroux R, Ringenbach C, Marchand T, et al. A new matrikine-derived peptide up-regulates longevity genes for improving extracellular matrix architecture. International Journal of Cosmetic Science. 2020 volume 42 issue 1 pages 53 to 59.
• Sederma. Matrixyl synthe’6 Technical Data Sheet. Croda International.

What Makes This Tripeptide Different

GHK-Cu is a naturally occurring copper peptide complex. Your body makes it from a simple three-amino-acid chain called glycyl-L-histidyl-L-lysine. That chain binds one copper ion to form GHK-Cu. At age twenty the average person has about two hundred nanograms per milliliter of this peptide circulating in their blood. By age sixty that number drops to around eighty nanograms per milliliter. This decline tracks closely with visible skin aging. And researchers have spent decades figuring out why.

Most skincare ingredients promise one thing. GHK-Cu does something fundamentally different. It does not just stimulate collagen or smooth a wrinkle. It appears to reset gene expression patterns that drift out of balance as skin ages. Loren Pickart, the biochemist who first isolated GHK from human plasma in 1973, later discovered that the copper-bound form regulates over four thousand human genes. Many of those genes shift toward healthier expression levels after GHK-Cu treatment. This is not a marketing claim. This is published data from a 2018 review in the International Journal of Molecular Sciences.

How GHK-Cu Works at the Molecular Level

Let me break this down into the three main pathways that matter for skin.

First, collagen and extracellular matrix remodeling. GHK-Cu stimulates fibroblasts, which are the cells that produce collagen, elastin, and glycosaminoglycans in your dermis. But it does something clever. It stimulates both the synthesis and the controlled breakdown of these structural proteins. This balanced remodeling is why GHK-Cu improves skin firmness without the stiff, fibrotic quality that some growth factors can produce. A 2015 review from Pickart and colleagues, published in BioMed Research International, documented that GHK increases production of collagen types one and three, dermatan sulfate, chondroitin sulfate, and decorin. Decorin is a small proteoglycan that organizes collagen fibrils into the right spatial arrangement. Without proper decorin, collagen accumulates in disorganized clumps. With it, collagen assembles into the neat basket-weave pattern of young skin.

Second, antioxidant defense through gene activation. GHK-Cu does not work like a vitamin C serum that directly scavenges free radicals molecule by molecule. Instead it turns on the cell’s own antioxidant machinery. A 2023 study in the Journal of Cachexia, Sarcopenia and Muscle showed that GHK-Cu directly binds and activates SIRT1, a protein deacetylase that regulates cellular stress resistance. SIRT1 activation then triggers a cascade. It deacetylates Nrf2, which migrates to the nucleus and switches on genes for superoxide dismutase, catalase, and glutathione synthesis. In plain language, GHK-Cu tells your skin cells to build their own antioxidant shield. This matters enormously because endogenous antioxidants are far more efficient than externally applied ones.

Third, inflammation resolution. Chronic low-grade inflammation is a hallmark of aging skin. Scientists call it inflammaging. GHK-Cu suppresses NF-kappa-B, a master transcription factor that drives inflammatory gene expression. At the same time it reduces levels of tumor necrosis factor alpha and other pro-inflammatory cytokines. The 2025 study by Hu and colleagues, published in Colloids and Surfaces B, confirmed that GHK-Cu loaded into a hydrogel filler reduced inflammatory factors and reactive oxygen species in both cell culture and living tissue. They observed significant collagen deposition alongside the anti-inflammatory effect. The copper connection. This is where the metal ion matters. Copper is not just a passive tag-along on the GHK peptide. It is the active center that enables GHK to bind its target proteins. Without copper, GHK has dramatically reduced biological activity. The copper ion coordinates with the histidine residue in GHK, creating a planar complex that fits precisely into binding pockets on SIRT1 and other regulatory proteins. This is why the GHK-Cu complex, not naked GHK, is the functional molecule. The molecular recognition depends on copper’s coordination geometry. Replace copper with zinc or iron and the activity changes entirely.

These three pathways do not operate in isolation. They reinforce each other. Less inflammation means less collagen degradation. Better antioxidant defense means less oxidative damage to fibroblasts. More organized collagen means better mechanical support for the epidermis above.

The Natural Decline and What It Means

Here is the key data point that brings all of this into focus. Human plasma GHK levels drop roughly sixty percent between age twenty and age sixty. That is from two hundred nanograms per milliliter down to eighty. A 2020 paper from the University of Washington, published in Aging Pathobiology and Therapeutics, reviewed this decline and its consequences. The authors noted that GHK’s anti-inflammatory and tissue remodeling properties make this drop particularly significant for skin aging. They also raised an intriguing possibility. Preliminary evidence suggested GHK can partially reverse cognitive impairment in aging mice. The skin effects are better studied. But the fact that one peptide influences both brain aging and skin aging tells you something about how fundamental its role is.

The copper part matters too. Without copper, GHK cannot form the active GHK-Cu complex, and its biological potency drops dramatically. Your skin naturally contains copper in the dermis. But that copper availability also declines with age because copper-binding proteins become less efficient. This creates a double deficit. Less GHK peptide plus less available copper equals progressively weaker tissue maintenance.

The Delivery Problem Nobody Talks About

Now here is the part that separates effective GHK-Cu products from expensive water.

GHK-Cu is a hydrophilic molecule. It dissolves readily in water. Your stratum corneum, the outermost layer of skin, is lipophilic. It repels water and lets oils through. This is the fundamental mismatch. A molecule that loves water struggles to cross a barrier that loves oil. A 2024 review by Mortazavi and colleagues from Shahid Beheshti University, published in BioImpacts, tackled this question directly. They concluded that yes, GHK-Cu does work as an anti-wrinkle ingredient at the cellular level. But its skin permeability is limited. The review described this as a surprising absence of clinical studies given how widely GHK-Cu is used in cosmetic products.

Chemists have developed several strategies to solve this. The most common is palmitoylation. Adding a sixteen-carbon fatty acid chain to GHK creates Pal-GHK, also known as palmitoyl tripeptide-1. That fatty tail makes the molecule more lipophilic and significantly improves penetration through the stratum corneum. Most commercial copper peptide serums use a blend of GHK-Cu and Pal-GHK for this reason.

A more recent approach is liposomal encapsulation. A 2025 review by Ogórek and colleagues from Warsaw University of Technology, published in Molecules, examined whether liposomes can deliver GHK-Cu through skin. Liposomes are tiny spherical vesicles made from phospholipids, the same material as cell membranes. They can encapsulate water-soluble cargo like GHK-Cu inside their aqueous core and then merge with skin cell membranes to release their payload. The review found that this approach has real promise but has received surprisingly little research attention. The authors called it a research gap.

There is also a physical approach. Microneedling creates microscopic channels through the stratum corneum. Applying GHK-Cu immediately after microneedling bypasses the barrier entirely. The Mortazavi review flagged this as a promising combination strategy. Several clinical protocols use exactly this approach for post-procedure recovery.

What the Clinical Evidence Actually Shows

The cellular data for GHK-Cu is robust. Decades of in vitro studies show consistent effects on collagen synthesis, antioxidant enzyme activation, and inflammatory cytokine suppression. The human data is thinner but still instructive.

Pickart’s 2015 review summarized cosmetic product results. GHK-Cu formulations tightened loose skin. They improved elasticity, skin density, and firmness. They reduced fine lines and wrinkles. They decreased photodamage and hyperpigmentation. They increased keratinocyte proliferation in the epidermis. These endpoints were measured in commercial product testing rather than randomized controlled trials. But the consistency across multiple independent formulations strengthens the case.

The wound healing literature provides additional evidence. GHK-Cu accelerates wound closure in skin, hair follicles, gastrointestinal tissue, and bone. A 2025 study by Chen and colleagues, published in Biomaterials Research, developed a GHK-Cu loaded hydrogel dressing for infected wounds. The dressing promoted neovascularization, reduced inflammation, and accelerated skin regeneration. While wound healing is not the same as cosmetic anti-aging, it demonstrates GHK-Cu’s tissue repair capabilities in living human-relevant models.

The numbers from wound healing studies are striking. GHK-Cu treatment at just zero point two to two milligrams per kilogram of body weight significantly increased muscle mass and grip strength in animal models of muscle wasting, as shown in the 2023 Deng study. At the cellular level, GHK-Cu at micromolar concentrations activates SIRT1 with a binding energy of negative six point one kilocalories per mole. That is a strong binding affinity comparable to many pharmaceutical drugs.

What about direct anti-wrinkle data in humans? This is where the evidence base gets thinner but still useful. Pickart’s cosmetic studies reported improvements in skin density, firmness, and fine line reduction. The effects appeared after four to twelve weeks of daily application. The Mortazavi 2024 review noted that while the cellular data is strong, the published clinical trial evidence specifically for wrinkle reduction is surprisingly sparse. This is a gap that cosmetic science needs to fill. But the mechanistic data, combined with consistent results from wound healing trials, makes a compelling circumstantial case.

The delivery studies add another piece to the puzzle. A 2025 investigation by Hu and colleagues showed that GHK-Cu loaded into a hydroxyapatite microsphere gel released the peptide continuously for seven days. This sustained release matters because GHK-Cu has a short half-life in free solution. The gel formulation maintained therapeutic concentrations at the target site for a full week. When tested in living tissue, it reduced inflammatory markers, increased superoxide dismutase activity, and promoted visible collagen deposition. The Masson trichrome staining showed thick, organized collagen bundles in the treated tissue compared to disorganized, sparse collagen in controls.

Expert Insight: What Most Formulations Get Wrong

Here is the anti-pattern that experienced formulators know and most brands ignore.

Concentration confusion. More is not better with GHK-Cu. At low concentrations, around zero point zero five to zero point two percent, GHK-Cu stimulates collagen and promotes healing. At higher concentrations, above roughly one percent, the effects can reverse. Copper becomes pro-oxidant rather than antioxidant. It generates reactive oxygen species instead of suppressing them. Many products on the market either use too little GHK-Cu to matter or too much to be safe. The therapeutic window matters enormously.

pH stability surprises. GHK-Cu is stable around neutral pH but degrades rapidly in acidic formulations. Many serums use glycolic acid, salicylic acid, or pure ascorbic acid at low pH. If you layer these with a GHK-Cu product, you may be destroying the peptide before it reaches your skin. The Mortazavi 2024 review highlighted this as a major formulation challenge. GHK-Cu needs a dedicated pH-stable vehicle. It should not share a bottle with exfoliating acids.

The blue color trap. GHK-Cu solutions are intensely blue in concentrated form. This is the copper ion’s natural color in aqueous solution. Many brands market this blue color as proof of potency. In reality, the blue color fades as GHK-Cu degrades, but it also fades when the formulation simply dilutes the peptide. A pale blue serum tells you nothing about peptide activity. Only independent stability testing can confirm whether the GHK-Cu in the bottle is still intact.

Compatibility blind spots. GHK-Cu does not play well with strong antioxidants in the same formulation. Vitamin C, in particular, can reduce the copper ion from its active Cu-two-plus state to inactive Cu-one-plus. This redox reaction destroys both ingredients. The same issue applies to resveratrol and certain forms of vitamin E. Experienced formulators keep GHK-Cu in dedicated products and advise users to separate application from antioxidants by at least thirty minutes. The freeze-dried advantage. This is what the most advanced brands do and mass-market products skip. GHK-Cu in aqueous solution degrades over weeks to months even at optimal pH. Lyophilization, which means freeze-drying the peptide into a dry powder, extends shelf life to years. The peptide stays stable as a powder and only gets mixed with a liquid vehicle immediately before use. This is why pharmaceutical peptide drugs are almost always lyophilized. Our own GHK-Cu product takes this approach. It ships as a freeze-dried powder with a separate activating solution. You mix them when you start the bottle, not months before at the factory.

Where GHK-Cu Fits in Your Routine

So how should you think about GHK-Cu alongside other peptides in your skincare?

GHK-Cu is a signal peptide. It tells your skin cells to behave more like young, healthy cells. This is fundamentally different from neurotransmitter-inhibiting peptides like Argireline and Snap-8, which work by temporarily relaxing facial muscles to reduce expression lines. It is also different from collagen-fragment peptides like Matrixyl, which trick fibroblasts into thinking collagen has been damaged so they produce more. GHK-Cu operates upstream of all of these. It improves the health of the fibroblast itself so that it produces better collagen, responds properly to signals, and defends itself against oxidative stress.

This means GHK-Cu pairs well with other peptides rather than competing with them. A morning routine might use Argireline or Snap-8 to address dynamic expression lines. An evening routine with GHK-Cu supports overnight tissue repair when fibroblast activity peaks. Some products combine GHK-Cu with Matrixyl for a dual approach to collagen signaling.

For best results, apply GHK-Cu to clean skin before heavier creams or oils. The peptide needs direct contact with the epidermis. If your product uses Pal-GHK rather than plain GHK-Cu, the palmitoyl modification helps with penetration. If you use microneedling, apply GHK-Cu within thirty minutes after the procedure.

One practical note about our own GHK-Cu serum. It uses a concentration within the therapeutic window I described, paired with a pH-optimized vehicle without competing actives. The copper peptide works best when it is the star of its own show, not a supporting character in a formula with ten other ingredients.

The Bigger Picture

GHK-Cu sits at an interesting intersection in peptide science. It is simultaneously one of the oldest studied cosmetic peptides and one of the most promising areas for future research. The gene expression data from Pickart’s lab suggests that GHK-Cu does not just patch individual signs of aging. It appears to recalibrate the epigenetic programs that cause those signs in the first place.

The delivery challenge remains the biggest limitation. A peptide that cannot reach the dermis in sufficient quantities cannot deliver on its molecular promise. But the formulation science is catching up. Liposomal encapsulation, palmitoylation, and combination with physical delivery methods like microneedling are closing the gap between what GHK-Cu can do in a petri dish and what it can do on your face.

Something to watch. The next generation of GHK-Cu products will likely use conjugated delivery systems rather than simple aqueous solutions. A 2025 study by Greco and colleagues, published in Bioconjugate Chemistry, conjugated GHK to hyaluronic acid, creating a hybrid molecule that combines the regenerative signaling of GHK-Cu with the hydrating and delivery-enhancing properties of hyaluronic acid. These conjugates showed enhanced osteogenic and angiogenic effects. The cosmetic applications are obvious and probably not far away.

I will be tracking those developments. This peptide’s story is still being written.

Further Reading

• Argireline: The Science Behind Acetyl Hexapeptide-8 — how neurotransmitter-inhibiting peptides compare to GHK-Cu’s signaling approach
• Snap-8: How Acetyl Octapeptide-3 Relaxes Expression Lines — another expression-line peptide with a different mechanism
• Peptide Stability in Skincare: pH and Formulation Science — why the bottle matters as much as the ingredient
• CKYN Launches Three-Step Copper Peptide Skincare Protocol — market news on copper peptide product innovation

Sources

• Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 2018, volume 19, issue 7, article 1987.
• Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015, article 648108.
• Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically Applied GHK as an Anti-Wrinkle Peptide: Advantages, Problems and Prospective. BioImpacts, 2024, volume 15, article 30071.
• Dou Y, Lee A, Zhu L, Morton J, Ladiges W. The Potential of GHK as an Anti-Aging Peptide. Aging Pathobiology and Therapeutics, 2020, volume 2, issue 1, pages 58 to 61.
• Deng M, Zhang Q, Yan L, et al. GHK-Cu Rescues Cigarette Smoking-Induced Skeletal Muscle Dysfunction via SIRT1. Journal of Cachexia, Sarcopenia and Muscle, 2023, volume 14, issue 3, pages 1365 to 1380.
• Hu D, Zhang X, Gong S, et al. An Injectable Hydroxyapatite Microsphere Filler Loaded with GHK-Cu Tripeptide. Colloids and Surfaces B: Biointerfaces, 2025, volume 256, part 1, article 114982.
• Ogórek K, Nowak K, Wadych E, Ruzik L, Timerbaev AR, Matczuk M. Are We Ready to Measure Skin Permeation of GHK-Cu Encapsulated in Liposomes? Molecules, 2025, volume 30, issue 1, article 136.
• Chen H, Yang P, Xue P, et al. Food-Derived Tripeptide-Copper Self-Healing Hydrogel for Infected Wound Healing. Biomaterials Research, 2025, volume 29, article 0139.
• Greco V, Lanza V, Tomasello B, et al. Copper Complexes with GHK-Hyaluronan Conjugates. Bioconjugate Chemistry, 2025, volume 36, issue 4, pages 662 to 675.

Last reviewed: July 2026. Peptide Proof Editorial Team.

Share this article: X · LinkedIn · Email

The Botox Problem Argireline Was Designed to Solve

Expression wrinkles form when facial muscles contract. Every smile, frown, and squint pulls the skin into the same folds thousands of times. Over years, those temporary creases become permanent lines. Crow’s feet. Forehead furrows. The “eleven” between the eyebrows.

For decades, botulinum toxin injections have been the gold standard. Botox, Dysport, Xeomin — they all block acetylcholine release at the neuromuscular junction. The muscle can’t contract. The skin smooths out. The effect lasts three to six months. But here’s the trade-off. A needle has to reach the right muscle at the right depth. Get it wrong and you get a drooping eyelid or a frozen expression. The procedure costs hundreds of dollars per session. And for many people, injecting a neurotoxin into their face is deeply unsettling.

This gap is exactly where Argireline lives. Lipotec, a Barcelona-based biotech company now part of Lubrizol, developed it around two thousand and two as a topical alternative to injectable neuromodulators. The idea was elegant: create a peptide small enough to penetrate skin, specific enough to target the same SNARE protein complex that Botox disrupts, and gentle enough to apply at home.

The cosmetic ingredient world gave it the clinical name acetyl hexapeptide-8. Chemically, it’s acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide — a six-amino-acid chain with an acetyl cap. But consumers know it by its trade name: Argireline. Google search volume for the term jumped substantially in twenty twenty-two. A JMIR Dermatology study tracked the trend. Searches for “Argireline” and “Botox in a Bottle” both spiked, while “Botox” searches remained stable and steadily rising over the prior decade. People want the needle-free option.

SNARE, SNAP-25, and the Molecular Mechanism

To understand how Argireline works, you need to understand what happens when a facial muscle fires. A nerve impulse travels down a motor neuron. It reaches the nerve terminal. Vesicles inside the terminal — tiny membrane-bound sacs — are loaded with acetylcholine, the neurotransmitter that tells muscles to contract. Those vesicles need to dock with the nerve cell membrane, fuse with it, and release their acetylcholine cargo into the synaptic cleft.

This docking and fusion is not random. It is orchestrated by the SNARE complex — Soluble NSF Attachment Protein Receptor. The complex is essentially a molecular zipper. Three proteins — synaptobrevin, syntaxin, and SNAP-25 — coil around each other to form an extremely stable four-helix bundle. That coiled bundle physically pulls the vesicle membrane against the nerve terminal membrane. The two membranes fuse. Acetylcholine spills out. The muscle contracts.

Here’s what makes Argireline clever. It mimics the N-terminal end of SNAP-25. That’s the part of the protein that interacts with the other two SNARE partners during complex assembly. When Argireline molecules are present at the nerve terminal, they compete with the natural SNAP-25 for a spot in the forming SNARE complex. But Argireline is incomplete — it’s just a fragment. So the complex assembles, but it’s unstable. It can’t generate the mechanical force needed to pull the vesicle and membrane together. Vesicle docking is disrupted. Acetylcholine release is reduced. The muscle gets a weaker signal to contract.

The critical difference from botulinum toxin is what Argireline does NOT do. Botulinum toxin enters the neuron and cleaves SNAP-25 — it destroys the protein entirely. Recovery takes weeks because the neuron needs to synthesize new SNAP-25. Argireline does not destroy anything. It is a competitive inhibitor. It sits in the binding pocket and prevents proper complex formation. When the Argireline concentration drops, normal SNARE assembly resumes. This is why Argireline is not permanent. It’s also why it’s safer — there is no risk of irreversible neuromuscular blockade.

This mechanism is well-established in molecular biology. SNAP-25 is one of the most studied proteins in neuroscience. The botulinum toxin serotypes A through G each target one of the three SNARE proteins. Botox serotype A and E cleave SNAP-25 specifically. Decades of research on botulinum toxin mechanism have mapped the exact binding interfaces that Argireline exploits. The peptide’s design was not guesswork — it was rational drug design based on the crystallographic structure of the SNARE complex.

The Delivery Challenge: Crossing the Stratum Corneum

Knowing how a peptide works inside the body is one thing. Getting it there through intact skin is another problem entirely. And this is where Argireline’s story gets complicated.

The stratum corneum — the outermost layer of the epidermis — is a formidable barrier. It’s a brick-and-mortar structure. Dead corneocytes are the bricks. Lipid bilayers composed of ceramides, cholesterol, and free fatty acids form the mortar. This arrangement evolved to keep water in and pathogens out. It is extremely effective at both. For a topical peptide to reach the neuromuscular junction, it must traverse the stratum corneum, navigate the viable epidermis, cross the dermal-epidermal junction, and diffuse through the dermis to reach motor nerve terminals — a journey of several hundred microns through progressively more hydrophilic environments.

Argireline faces specific challenges here. It has a molecular weight of about eight hundred and eighty-nine daltons. That’s already pushing against the “five hundred Dalton rule” — the general observation that molecules larger than five hundred daltons struggle to penetrate intact skin. More importantly, Argireline is hydrophilic. It dissolves readily in water. But the stratum corneum lipid matrix is hydrophobic. A water-loving peptide bounces off an oil-based barrier. This is the fundamental mismatch that every Argireline formulation must solve.

A twenty twenty-five review in the International Journal of Molecular Sciences, by Zdrada-Nowak and colleagues, is the most comprehensive analysis of this problem to date. They surveyed the full body of AH-8 literature. Their conclusion: preclinical and clinical studies indicate Argireline may reduce wrinkle depth, improve skin elasticity, and enhance hydration. But the peptide’s low skin penetration limits its bioavailability. Whether AH-8 can actually reach neuromuscular junctions in meaningful concentrations when applied topically “remains uncertain.”

But here’s where the story gets more interesting. The delivery problem is not unsolvable. It’s a formulation problem. And researchers are solving it.

A twenty twenty-six study by Yi and colleagues, published in the Journal of Craniofacial Surgery, tested a cooling-assisted delivery device called TargetCool. They applied acetyl hexapeptide-8 tagged with a fluorescent marker to ex vivo human facial skin from Korean donors aged fifty to seventy. Compared to simple topical application, the fluorescence intensity — a direct measure of how much peptide got into the skin — increased by five hundred and four percent with a shallow microneedle device. It jumped by seven hundred percent with a deeper microneedle system. But the real breakthrough was the combination. Shallow microneedles plus TargetCool produced a twelve hundred and seventy-two percent increase in peptide penetration. The penetration depth increased by nearly thirty-seven percent. And there was no structural damage to the skin tissue.

Another twenty twenty-six study, from Feng and colleagues in the International Journal of Biological Macromolecules, took a different approach. They developed dissolving microneedles — tiny polymer needles loaded with acetyl hexapeptide-8. Press the patch onto skin. The needles penetrate the stratum corneum and dissolve. The peptide releases directly into the viable epidermis and dermis. In pig skin models, cumulative transdermal delivery reached eleven point three percent — far higher than an aqueous solution of the same peptide. When tested on photoaged mice, these microneedles significantly reduced visible wrinkles, improved skin elasticity, and restored hydration.

A twenty twenty-five study from the Journal of Materials Chemistry B, by Wang and colleagues, combined acetyl hexapeptide-8 with a bioactive ionic liquid derived from malic acid. The ionic liquid reduced the free energy barrier for peptide permeation through the lipid matrix. In vitro, the twenty-four hour cumulative permeation was three point one times that of free peptide. After twenty-eight days in a clinical trial, subjects using the ionic liquid system showed greater reductions in wrinkle number, length, and area than those using standard Argireline cream.

Two more approaches show where the field is heading. A team led by Rong at East China Normal University developed fluorous oligoarginines — fluorinated cell-penetrating peptides that act as “super-enhancers” for transdermal delivery, publishing in Bioactive Materials in twenty twenty-five. And Hou and colleagues at Beijing Youngen Biotechnology engineered plant-derived exosomes as nanocarriers for AH-8. Published in ACS Applied Bio Materials in twenty twenty-four, their tissue slice studies confirmed the exosome carriers delivered acetyl hexapeptide-8 efficiently to the dermis, outperforming free peptide.

The delivery problem is real. But the solution is coming — through microneedles, ionic liquids, nanocarriers, and chemical penetration enhancers. The barrier that limits today’s Argireline serums will not be the barrier of tomorrow.

What the Clinical Data Actually Shows

Let’s look at the numbers that matter. The most rigorous recent clinical data comes from a twenty twenty-six L’Oréal study published in the International Journal of Cosmetic Science. Zhu and colleagues tested a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate, gluconolactone, niacinamide, and laminaria extract.

Two clinical trials were run. Study one had fifty subjects and focused on static wrinkles. Study two had forty-two subjects and focused on dynamic wrinkles. Static wrinkle appearance improved significantly within the first week. After twelve weeks, mean clinical scoring improvements ranged from thirty-five to sixty-nine percent for different wrinkle types. All results were statistically significant. Dynamic wrinkles improved by ten to thirteen percent. Skin quality also shifted: smoothness up thirty percent, radiance up twenty-seven percent, pore appearance improved forty-three percent, elasticity up thirty-three percent, and firmness up thirty-six percent.

Now here’s the key data point. The ex vivo arm of this study analyzed biomarkers in human skin samples. The serum significantly increased levels of elastic fibers and multiple collagen types including type one, type three, type four, and type seventeen. It also reduced matrix metalloproteinase-1 — the enzyme that breaks down collagen. So this was not just a surface-level cosmetic effect. There were measurable changes in the skin’s structural proteins.

But context matters. That serum contained five active ingredients. Argireline was not tested alone. The collagen and elastin boosts could come from the niacinamide, the laminaria extract, the gluconolactone, or the synergistic combination of all five. This is the honest read of the data. Argireline’s mechanism is neuromuscular — it should reduce dynamic wrinkles by relaxing muscle contraction. That’s what the ten to thirteen percent dynamic wrinkle improvement reflects. The bigger static wrinkle improvements likely come from the formula’s other actives stimulating collagen synthesis.

Safety data is clearer and more definitive. In twenty twenty-five, the Expert Panel for Cosmetic Ingredient Safety published their review of acetyl hexapeptide-8 amide in the International Journal of Toxicology. Their conclusion: the ingredient is safe in cosmetics at concentrations up to zero point zero zero five percent. They did not have sufficient data to declare it safe above that concentration. Most commercial Argireline products market themselves as “ten percent Argireline.” That means ten percent of the commercial Argireline stock solution, which is itself diluted. The actual acetyl hexapeptide-8 concentration in finished products is far lower, usually in the zero point zero zero one to zero point zero zero five percent range. This matches the CIR safety threshold.

Additional safety evidence comes from zebrafish models. A twenty twenty-five study by Jiang and colleagues in the Journal of Cosmetic Dermatology found that acetyl hexapeptide-8 combined with bakuchiol showed moisturizing, anti-inflammatory, and antioxidant bioactivity with no toxicity. The combination was more effective than either ingredient alone. Treated embryos showed reduced water loss, improved expression of skin tightness genes including elastin and collagen, and restored telomerase activity after oxidative stress.

Expert Insight: What Experienced Formulators Know

I’ve spent years tracking peptide skincare formulation. Here are four things the data doesn’t tell you and the marketing definitely won’t.

The concentration sweet spot is narrow. “Ten percent Argireline” or “twenty percent peptide complex” on a label refers to the commercial solution, not the pure peptide. The actual acetyl hexapeptide-8 concentration is much lower. Too little and the competitive inhibition at the SNARE complex is too weak. Too much and you exceed the CIR safety threshold. Experienced formulators target the highest safe concentration and verify with penetration data, not just ingredient percentage on the label.

The penetration problem is bigger than most brands admit. Even with microneedling, acetyl hexapeptide-8 penetration depth increased by only thirty-three to forty-eight percent compared to untreated skin. Without enhancement, the base penetration from simple topical application is very low. If your Argireline serum is just water, glycerin, and peptide, most of that peptide is sitting on your stratum corneum and washing off at the next cleanse. Look for formulations with penetration technology: ethosomes, liposomes, microemulsions, or glycol-based enhancers. If the brand isn’t talking about how the peptide gets into your skin, it probably isn’t getting very far.

Degradation in formulation is real. Peptides are fragile. Acetyl hexapeptide-8 is a short chain, six amino acids, with an acetyl cap that provides some protection. But it is still susceptible to hydrolysis in acidic conditions and oxidation over time. Argireline is most stable at a pH between five and seven. Below five, the peptide bonds start to hydrolyze. Above seven, deamidation can occur at the glutamine residues. In a poorly buffered formula that drifts acidic over its shelf life, you might be applying degraded peptide fragments by month three. Always check whether the brand provides pH stability data or accelerated aging test results.

The “Botox in a bottle” label is doing more harm than good. Argireline is not Botox. It does not cleave SNAP-25. It competes with SNAP-25 at a binding site. The effect is milder, shorter-lasting, and limited by penetration depth. Calling it “Botox in a bottle” sets an impossibly high expectation. When a consumer tries Argireline and doesn’t get Botox-level results in three days, they dismiss the entire peptide category. The honest framing: Argireline is a topical peptide that partially reduces the muscle contraction behind expression lines. Results accumulate over weeks, not days. It’s best for early-to-moderate lines in people not ready for injectables. That’s a compelling value proposition on its own. It doesn’t need the Botox comparison.

Argireline in Your Routine: Practical Context

So where does Argireline fit in a real skincare routine? The answer depends on what else you’re using and what problem you’re solving.

Argireline targets expression wrinkles — crow’s feet, forehead lines, the “eleven” between the brows. It does not target static wrinkles caused by collagen loss, sun damage, or glycation. For those, you need signal peptides like Matrixyl or copper peptides like GHK-Cu. The best results come from combining them. Argireline in the morning to relax muscle-driven creasing. A signal peptide at night to rebuild structural proteins. Our Matrixyl deep dive covers the collagen signaling pathway. Our Snap-8 article explains how a related inhibitory peptide takes a different approach to the same SNARE target.

Order of application matters. Peptides are water-soluble and need to reach living skin. Apply your Argireline serum immediately after cleansing, before any oils or occlusives. Give it a minute to absorb before layering. If you use a vitamin C serum in the morning too, apply the vitamin C first. It needs a lower pH to penetrate. Argireline is stable across a broader pH range. Wait for the vitamin C to absorb, then layer the peptide.

Consistency is everything with peptides. You are not destroying a protein like Botox does. You are competing with natural SNAP-25 in a binding equilibrium that shifts as the peptide concentration in your tissue changes. Skip a day and your Argireline concentration drops. The SNARE complexes assemble normally. Your expression lines return. This is a daily maintenance protocol, not a one-time treatment. Twice-daily application gives the best published results. The L’Oréal clinical data showed visible improvement starting in the first week. But the maximum benefit — that thirty-five to sixty-nine percent range — came at twelve weeks. Be patient.

If you’re using Argireline specifically for forehead lines or the “eleven” between your brows, application technique matters more than most people realize. You need the peptide to reach the muscles underneath that skin. Apply directly to the target area. A pea-sized drop tapped gently into the frown line area is more effective than a full-face layer that never reaches therapeutic concentration at the neuromuscular junction. This is about focused delivery to the right anatomical location. The corrugator supercilii muscle for the “eleven,” the frontalis for forehead lines, the orbicularis oculi for crow’s feet.

One last practical note. Our site carries an Argireline serum formulated at the optimal concentration for daily use. It ships from Berlin across the EU with flat-rate shipping and free delivery on orders over eighty euros. If you want to add a targeted expression-line peptide to your routine, that product was designed to solve exactly this problem.

Further Reading

• Snap-8: How Acetyl Octapeptide-3 Relaxes Expression Lines — A companion inhibitory peptide targeting the same SNARE pathway with a longer amino acid chain
• Matrixyl: How Palmitoyl Pentapeptide-4 Triggers Collagen — The signal peptide that rebuilds structural proteins. Best paired with Argireline for comprehensive anti-aging
• Peptide Stability in Skincare: pH, Temperature, and Formulation Science — Why your peptide serum might be degrading before it reaches your skin
• Syn-Ake: The Snake Venom Peptide That Smooths Wrinkles — A different neuromuscular approach to the same expression line problem

---

Argireline Deep Dive: Acetyl Hexapeptide-8 and Expression Lines

Last reviewed: July 2026. Peptide Proof Editorial Team.

Sources: Zdrada-Nowak J et al., International Journal of Molecular Sciences, 2025 volume 26 issue 12 page 5722. Zhu M et al., International Journal of Cosmetic Science, 2026. Yi KH et al., Journal of Craniofacial Surgery, 2026. Feng M et al., International Journal of Biological Macromolecules, 2026 volume 346 page 150669. Wang Z et al., Journal of Materials Chemistry B, 2025 volume 13 issue 30 pages 9286 to 9293. Rong G et al., Bioactive Materials, 2025 volume 59 pages 305 to 316. Johnson W et al., International Journal of Toxicology, 2025 volume 44 supplement 2 pages 54S to 63S. Jiang X et al., Journal of Cosmetic Dermatology, 2025 volume 24 issue 4 page e70128. Olsson SE et al., JMIR Dermatology, 2024 volume 7 page e54217. Hou J et al., ACS Applied Bio Materials, 2024 volume 7 issue 5 pages 3050 to 3060.